News | May 04, 2026
Lilly posts explosive Q1 2026 results
Lifts full-year outlook as obesity drug boom accelerates
Lifts full-year outlook as obesity drug boom accelerates
The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 3 to 6 against recommending camizestrant in combination with a CDK4/6 inhibitor
Rahul Bhatnagar succeeds Aditya Narayan, who completed a decade-long distinguished tenure
The company posted revenue of €1,267 million, up 6% on a constant currency basis
The company posted revenue of Rs. 703 crore in Q4 FY26
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
Stroke is the second-leading cause of death and the third-leading cause of disability worldwide
The 4,000-square-foot facility is designed as a hands-on hub where customers can work directly with scientists and engineers
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
